The University of Texas MD Anderson Cancer Center.
Duke Cancer Institute.
J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883. doi: 10.6004/jnccn.2019.0033.
Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.
食管癌是全球第六大癌症相关死亡原因。在东欧和亚洲，鳞状细胞癌是最常见的组织学类型，而在北美和西欧，腺癌最为常见。手术是治疗局部晚期可切除食管和食管胃交界（EGJ）癌的主要组成部分，随机试验表明，术前放化疗或围手术期化疗联合手术可显著提高生存率。曲妥珠单抗、雷莫芦单抗和帕博利珠单抗等靶向治疗在治疗晚期或转移性疾病的患者中取得了令人鼓舞的结果。多学科团队管理对于所有食管和 EGJ 癌症患者都是至关重要的。本 NCCN 食管癌和食管胃交界癌指南选段重点介绍了局部晚期和转移性食管和 EGJ 腺癌的管理建议。
